Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036452 · ClinicalTrials.gov registry record · Phase 2
A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 402
- Enrollment target
NCT00036452 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 402 participants.
The verdict
NCT00036452, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 402 participants
- Enrollment target
Study Summary
Anti-HIV drug therapy works best when the drugs are taken exactly as prescribed by a doctor. Because anti-HIV therapy often involves multiple drugs, some people have difficulty taking them all correctly. The easier it is to take anti-HIV drugs, the more likely people will take them as prescribed and get the best results. This study will see if people are more successful in taking anti-HIV drugs once a day or twice a day. It also will determine if having a health care professional oversee each weekday dose helps people control their HIV infection. The study will compare taking a three-drug combination twice a day versus taking a three-drug combination just once a day. The study will also compare patients taking the drugs on their own to patients taking the drugs in the presence of a clinical worker. Viral load (amount of HIV in the blood) and drug side effects will be measured.
Interventions
- DRUG emtricitabine
- DRUG lopinavir/ritonavir
- DRUG stavudine
- DRUG tenofovir DF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 402 participants |
| Est. Completion | 2006-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00036452
The ClinicalTrials.gov registry entry for NCT00036452 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 402 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which emtricitabine is the first listed.
NCT00036452 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00036452 about?
NCT00036452 is a clinical study titled "A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation". Anti-HIV drug therapy works best when the drugs are taken exactly as prescribed by a doctor. Because anti-HIV therapy often involves multiple drugs, some people have difficulty taking them all correctly. The easier it is to take anti-HIV drugs, the more likely people will take them as prescribed and...
What is the current status of trial NCT00036452?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 402 participants. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00036452?
The interventions under investigation include: emtricitabine (DRUG), lopinavir/ritonavir (DRUG), stavudine (DRUG), tenofovir DF (DRUG).
Who is sponsoring clinical trial NCT00036452?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.